Buffalo Biolabs, LLC

Buffalo, NY 14203

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $1.73MM
First Award Date 07/01/09
Most Recent Award Date 07/01/17

Key Personnel

Last Name Name Awards Contact
Mal Asoke K Mal 1
Gurova Katerina Gurova 2
Sen Arindam Sen 1
Burkhart Catherine A Burkhart 1
Chernova Olga B Chernova 1
METT VADIM METT 3

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 07/01/17 - 06/30/18

PROJECT SUMMARY/ABSTRACT Antiviral vaccines remain the largest segment of the rapidly growing global vaccine market. Despite near-complete eradication of poliovirus through vaccination efforts, continued need for inactivated polio vaccine (IPV) is projected to reach 450 million doses per year worldwide. Among major obstacles to widespread use of...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 07/01/16 - 06/30/17

PROJECT SUMMARY/ABSTRACTAntiviral vaccines remain the largest segment of the rapidly growing global vaccine market.Despite near-complete eradication of poliovirus through vaccination efforts, continued need forinactivated polio vaccine (IPV) is projected to reach 450 million doses per year worldwide.Among major obstacles to widespread use of the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 07/01/14 - 12/31/14

ABSTRACT: Radiotherapy is widely used to treat various types of cancer;however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tissues in the tumor environment. Due to the scale of this problem and the current lack of safe and effective countermeasures against radiation toxicit...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-100
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determining the therapeutic potential of a new class of candidate anti-cancer agents named Curaxins (CXs) for treatment of PDA. The rationale for this is ba...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/24/12 - 08/31/13

DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It accounts for 3.5% of all malignancies in children. Despite multimodality therapeutic treatment approaches, the outlook for patients with metastatic subtyp...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/05/12 - 08/31/13

DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determining the therapeutic potential of a new class of candidate anti-cancer agents named Curaxins (CXs) for treatment of PDA. The rationale for this is ba...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/01/09 - 08/31/11

DESCRIPTION (provided by applicant): One of the major problems in the fight against cancer is the intrinsic or acquired resistance of tumors to current cancer treatments, particularly that associated with multidrug transporters (MDT;e.g. P-glycoprotein (P-gp) and the multidrug associated protein (MRP1)). The clinical failures of early P-gp inhib...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 07/01/09 - 06/30/10

DESCRIPTION (provided by applicant): Systemic treatment with the bacterial flagellin protein, a Toll-like receptor 5 (TLR5) agonist, provides protection against high dose radiation through activation of nuclear factor-(B (NF-(B). NF-(B signaling induces multiple factors that contribute to cell survival and tissue regeneration, including apoptosi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 07/01/09 - 06/30/10

DESCRIPTION (provided by applicant): Advances in treatment strategies have increased the long-term survival of children with acute lymphoblastic leukemia (ALL). However, the outlook of infants with ALL remains dismal with long-term survival rates of only 30-50%. Therefore, new treatments are desperately needed. Translocation of the mixed lineage...